An Update of Emerging Therapeutics to Prevent Stroke in Patients with Non-Valvular Atrial Fibrillation
This Official Elsevier Meeting Reporter will highlight recent science and clinical strategies for the management of patients with atrial fibrillation presented at the American Heart Association Scientific Sessions 2016 held in New Orleans, Louisiana. Expert faculty will discuss anticoagulant management, including prevention, diagnostic criteria and current treatment options. Updates on existing tactics for preventing stroke in the population of patients with atrial fibrillation will also be covered in the duration of this discussion-based activity. Faculty will relay optimal methods for educating newly diagnosed individuals and improving patient-physician communication lines as treatment progresses. Upon completion of this program, learners will find themselves better acquainted with the current science needed for accurate diagnosis as well as quality of life improvement in patients with atrial fibrillation.
This activity has been designed to meet the educational needs of health care professionals involved in the diagnosis, treatment, or management of patients with atrial fibrillation.
Upon completion of this activity, participants will be better able to do the following:
- Discuss atrial fibrillation science, including diagnostic criteria, prevention and treatment options.
- Analyze clinical trial data for emerging reversal therapeutics for stroke prevention in patients with atrial fibrillation as presented at AHA 2016.
- Integrate patient education and communication strategies into individualized treatment plans to reduce the risk of stroke in patients with non-valvular atrial fibrillation.
Michael D. Ezekowitz, MD, PhD
Charles V. Pollack, MD
Christian T. Ruff, MD, MPH
Disclosure of Conflicts of Interest
It is the policy of the Elsevier Office of Continuing Medical Education that all faculty, instructors, and planners disclose real or apparent conflicts of interest relating to the topics of this educational activity.
The faculty reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME activity:
|Faculty||Relationship Identified With:|
|Michael D. Ezekowitz, MD, PhD|
Consultant/Advisor: Aegerion Pharmaceuticals, Inc.; Amgen Inc.; Armetheon, Inc.; Bayer AG; Boehringer Ingelheim Pharmaceuticals, Inc.; Bristol-Myers Squibb Company; Coherex Medical; Daiichi Sankyo Company, Limited; Gilead; Janssen Global Services, LLC; Johnson & Johnson Services, Inc.; Medtronic; Merck & Co., Inc.; Pfizer Inc.; POZEN Inc.; sanofi-aventis U.S. LLC.
|Charles V. Pollack, MD|
Consultant/Advisor: Boehringer Ingelheim Pharmaceuticals, Inc.; Bristol-Myers Squibb Company; Janssen Global Services, LLC; Pfizer Inc.Grant/Research Support: Boehringer Ingelheim Pharmaceuticals, Inc.; Bristol-Myers Squibb Company; CSL Behring; Daiichi Sankyo Company; Janssen Global Services, LLC; Pfizer Inc.; Portola Pharmaceuticals, Inc.
Christian T. Ruff, MD, MPH
Consultant/Advisor: Bayer AG; Boehringer Ingelheim Pharmaceuticals, Inc.; Daiichi Sankyo Company; Portola Pharmaceuticals, Inc.Grant/Research Support: Daiichi Sankyo Company
Non-faculty: Timothy Hayes, MD, PhD; Emma Gilmartin; Nicole Brestowski; Sandy Breslow; Alison Kemp; Bernard M. Abrams, MD and Leah Johnson hereby state that neither they nor their spouse/life partner have any financial relationships to products or devices with any commercials interest related to the content of this activity of any amount during the past 12 months.
This activity has been supported by an independent educational grant from Boehringer Ingelheim Pharmaceuticals, Inc.
Co-provided by the Elsevier Office of Continuing Medical Education and AcademicCME.
CME Credit (Physicians)
The Elsevier Office of Continuing Medical Education is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
The Elsevier Office of Continuing Medical Education designates this enduring activity for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
CME INQUIRIES/SPECIAL NEEDS
For all CME inquiries or special needs, please contact elsevierCME@elsevier.com.
Disclosure of Unlabeled Use: This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The Elsevier Office of Continuing Medical Education, AcademicCME and Boehringer Ingelheim Pharmaceuticals, Inc. do not recommend the use of any agent outside of the labeled indications.
Disclaimer: Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications on dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.
- 1.00 AMA PRA Category 1 Credit(s)™
- 1.00 Non-physician